ASCO 2018 News - Episode 4
We are on site at McCormick Place in Chicago at the 2018 ASCO Annual Meeting!
First, we’ll be recapping some of the top news presented from the day, and then we’ll speak with Drs Tanios Bekaii-Saab on pancreatic cancer and Michael Birrer and Shannon Westin on the latest abstracts in ovarian cancer.
Welcome to OncLive News Network! I’m Gina Columbus.
In a cohort from the phase III CheckMate-227 trial, frontline treatment with nivolumab plus chemotherapy improved progression-free survival versus chemotherapy in patients with advanced non—small cell lung cancer and less than 1% tumor PD-L1 expression. The doublet regimen was also well tolerated.
Part 2 of CheckMate-227 Part 2 is ongoing and is exploring the immunotherapy combination versus chemotherapy alone, regardless of PD-L1 expression.
In non—small cell lung cancer, results of the phase III IMpower150 trial showed a significant benefit in overall survival with atezolizumab plus carboplatin and paclitaxel and bevacizumab versus chemotherapy and bevacizumab alone in the frontline setting for patients with nonsquamous NSCLC.
Moreover, in the phase III IMpower131 study, the addition of atezolizumab to frontline carboplatin and nab-paclitaxel delayed the risk of progression or death by 29% versus chemotherapy alone for patients with advanced squamous NSCLC.
Dacomitinib was found to improve overall survival when compared with gefitinib in patients in the phase III ARCHER 1050 study. The median OS was 34.1 months with dacomitinib versus 26.8 months.
The randomized phase III PRODIGE 7 trial demonstrated that patients with advanced colorectal cancer may not require heated chemotherapy delivered to the abdomen during surgery. Results showed that there was no difference in survival between patients with metastases in the abdomen who received heated chemotherapy during surgery and versus surgery alone.
Findings from the randomized phase III PRODIGE 24/CCTG PA.6 study showed that patients with resectable pancreatic cancer who received mFOLFIRINOX lived a median of 20 months longer and were disease free 9 months longer versus those who received standard gemcitabine.
For a full review of these topics, please visit OncLive.com.
That’s all for today.
Thank you for watching OncLive News Network: On Location in Chicago! I’m Gina Columbus.